Wall Street Zen Downgrades Omeros (NASDAQ:OMER) to Sell

Wall Street Zen lowered shares of Omeros (NASDAQ:OMER) from a hold rating to a sell rating in a research note issued to investors on Friday.

Other analysts have also recently issued reports about the stock. D. Boral Capital restated a “buy” rating and set a $36.00 price objective on shares of Omeros in a research note on Tuesday, May 13th. Needham & Company LLC restated a “hold” rating on shares of Omeros in a research note on Friday, May 16th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Omeros has an average rating of “Moderate Buy” and a consensus price target of $22.50.

Omeros Stock Up 14.2%

OMER stock opened at $3.77 on Friday. The firm has a 50 day moving average of $5.45 and a 200 day moving average of $7.94. The stock has a market capitalization of $220.90 million, a PE ratio of -1.63 and a beta of 2.20. Omeros has a 52 week low of $2.97 and a 52 week high of $13.60.

Omeros (NASDAQ:OMER) last announced its quarterly earnings data on Thursday, May 15th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.05). On average, equities research analysts expect that Omeros will post -3.09 earnings per share for the current year.

Institutional Trading of Omeros

Institutional investors and hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC increased its holdings in shares of Omeros by 21.2% during the 4th quarter. SG Americas Securities LLC now owns 24,361 shares of the biopharmaceutical company’s stock valued at $241,000 after purchasing an additional 4,257 shares in the last quarter. New York State Common Retirement Fund increased its holdings in shares of Omeros by 245.4% during the 4th quarter. New York State Common Retirement Fund now owns 17,313 shares of the biopharmaceutical company’s stock valued at $171,000 after purchasing an additional 12,300 shares in the last quarter. US Bancorp DE purchased a new position in shares of Omeros during the 4th quarter valued at approximately $81,000. Raymond James Financial Inc. purchased a new position in shares of Omeros during the 4th quarter valued at approximately $124,000. Finally, AlphaQuest LLC purchased a new position in shares of Omeros during the 4th quarter valued at approximately $285,000. 48.79% of the stock is currently owned by institutional investors and hedge funds.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.